With regard to the biodistribution of the 68Ga-NOTA-anti-HER2 nanobody, a relatively high uptake was observed in the kidneys, liver, and intestines, but a low background level was noted in all other organs typically affected by breast cancer metastases [58]. Here, ERBB2 is linked to breast cancer.